{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:21:12Z","timestamp":1787444472005,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,22]]},"DOI":"10.7759\/cureus.114995","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:29:21Z","timestamp":1787441361000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum Potassium and Mineralocorticoid Receptor Antagonists As Modifiers of Atrial Arrhythmia Recurrence After Catheter Ablation for Atrial Fibrillation: A Narrative Review With Systematic Search and Mechanistic Synthesis"],"prefix":"10.7759","author":[{"given":"Shunichiro","family":"Tomota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder IC","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al.. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024, 45:3314-414. 10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar JA","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al.. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024, 149:e1-e156. 10.1161\/CIR.0000000000001193","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae043","article-title":"2024 European Heart Rhythm Association\/Heart Rhythm Society\/Asia Pacific Heart Rhythm Society\/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"26","author":"Tzeis S","year":"2024","unstructured":"Tzeis S, Gerstenfeld EP, Kalman J, et al.. 2024 European Heart Rhythm Association\/Heart Rhythm Society\/Asia Pacific Heart Rhythm Society\/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024, 26:043. 10.1093\/europace\/euae043","journal-title":"Europace"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins H","year":"2017","unstructured":"Calkins H, Hindricks G, Cappato R, et al.. 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017, 14:e275-444. 10.1016\/j.hrthm.2017.05.012","journal-title":"Heart Rhythm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.004549","article-title":"Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis","volume":"2","author":"Ganesan AN","year":"2013","unstructured":"Ganesan AN, Shipp NJ, Brooks AG, et al.. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013, 2:e004549. 10.1161\/JAHA.112.004549","journal-title":"J Am Heart Assoc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2010.10.047","article-title":"Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up","volume":"8","author":"Naruse Y","year":"2011","unstructured":"Naruse Y, Tada H, Sekiguchi Y, et al.. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up. Heart Rhythm. 2011, 8:335-41. 10.1016\/j.hrthm.2010.10.047","journal-title":"Heart Rhythm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.08.048","article-title":"Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study","volume":"168","author":"Krijthe BP","year":"2013","unstructured":"Krijthe BP, Heeringa J, Kors JA, Hofman A, Franco OH, Witteman JC, Stricker BH. Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol. 2013, 168:5411-5. 10.1016\/j.ijcard.2013.08.048","journal-title":"Int J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.315641","article-title":"Hypokalemia promotes arrhythmia by distinct mechanisms in atrial and ventricular myocytes","volume":"126","author":"Tazmini K","year":"2020","unstructured":"Tazmini K, Frisk M, Lewalle A, et al.. Hypokalemia promotes arrhythmia by distinct mechanisms in atrial and ventricular myocytes. Circ Res. 2020, 126:889-906. 10.1161\/CIRCRESAHA.119.315641","journal-title":"Circ Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of hypokalemia and hyperkalemia","volume":"10","author":"Weiss JN","year":"2017","unstructured":"Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017, 10:004667. 10.1161\/CIRCEP.116.004667","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2024.06.020","article-title":"Association between the preprocedural serum potassium level and atrial fibrillation recurrence after catheter ablation","volume":"21","author":"Yang Z","year":"2024","unstructured":"Yang Z, Wang J, Jiang C, et al.. Association between the preprocedural serum potassium level and atrial fibrillation recurrence after catheter ablation. Heart Rhythm. 2024, 21:2429-36. 10.1016\/j.hrthm.2024.06.020","journal-title":"Heart Rhythm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.04.038","article-title":"A systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation","volume":"199","author":"Fatima K","year":"2023","unstructured":"Fatima K, Asad D, Shaikh N, et al.. A systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation. Am J Cardiol. 2023, 199:85-91. 10.1016\/j.amjcard.2023.04.038","journal-title":"Am J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad811","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials","volume":"45","author":"Oraii A","year":"2024","unstructured":"Oraii A, Healey JS, Kowalik K, et al.. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials. Eur Heart J. 2024, 45:756-74. 10.1093\/eurheartj\/ehad811","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013267","article-title":"Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors","volume":"8","author":"Alexandre J","year":"2019","unstructured":"Alexandre J, Dolladille C, Douesnel L, et al.. Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors. J Am Heart Assoc. 2019, 8:e013267. 10.1161\/JAHA.119.013267","journal-title":"J Am Heart Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal R","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021, 42:152-61. 10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone S","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, et al.. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018, 6:41-50. 10.1016\/S2213-8587(17)30319-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer GL","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018, 3:768-74. 10.1001\/jamacardio.2018.2003","journal-title":"JAMA Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder JW","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al.. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016, 101:1889-916. 10.1210\/jc.2015-4061","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91898","article-title":"Effect of esaxerenone in patients with persistent atrial fibrillation and hypertension after catheter ablation","volume":"17","author":"Kashiwagi M","year":"2025","unstructured":"Kashiwagi M, Kuroi A, Higashimoto N, et al.. Effect of esaxerenone in patients with persistent atrial fibrillation and hypertension after catheter ablation. Cureus. 2025, 17:e91898. 10.7759\/cureus.91898","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.03.429","article-title":"Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis","volume":"85","author":"Pabon MA","year":"2025","unstructured":"Pabon MA, Filippatos G, Claggett BL, et al.. Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis. J Am Coll Cardiol. 2025, 85:1649-60. 10.1016\/j.jacc.2025.03.429","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.0848","article-title":"Finerenone and atrial fibrillation in heart failure: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Matsumoto S","year":"2025","unstructured":"Matsumoto S, Henderson AD, Jhund PS, et al.. Finerenone and atrial fibrillation in heart failure: a secondary analysis of the FINEARTS-HF randomized clinical trial. JAMA Cardiol. 2025, 10:696-707. 10.1001\/jamacardio.2025.0848","journal-title":"JAMA Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.12.020","article-title":"Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation","volume":"111","author":"Ito Y","year":"2013","unstructured":"Ito Y, Yamasaki H, Naruse Y, et al.. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am J Cardiol. 2013, 111:1012-8. 10.1016\/j.amjcard.2012.12.020","journal-title":"Am J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23659","article-title":"Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: a single-center randomized controlled study","volume":"44","author":"Wang W","year":"2021","unstructured":"Wang W, Chen Q, Zhang F, et al.. Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: a single-center randomized controlled study. Clin Cardiol. 2021, 44:1120-7. 10.1002\/clc.23659","journal-title":"Clin Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-017-0302-2","article-title":"Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker","volume":"51","author":"Kiuchi MG","year":"2018","unstructured":"Kiuchi MG, Chen S, Hoye NA, P\u00fcrerfellner H. Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. J Interv Card Electrophysiol. 2018, 51:51-9. 10.1007\/s10840-017-0302-2","journal-title":"J Interv Card Electrophysiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell M","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, et al.. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020, 368:l6890. 10.1136\/bmj.l6890","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.17888","article-title":"Potassium supplementation and prevention of atrial fibrillation after cardiac surgery: the TIGHT K randomized clinical trial","volume":"332","author":"O'Brien B","year":"2024","unstructured":"O'Brien B, Campbell NG, Allen E, et al.. Potassium supplementation and prevention of atrial fibrillation after cardiac surgery: the TIGHT K randomized clinical trial. JAMA. 2024, 332:979-88. 10.1001\/jama.2024.17888","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.20-346","article-title":"The effect of renin-angiotensin system inhibitors on the recurrence of atrial fibrillation after catheter ablation","volume":"61","author":"Zhao J","year":"2020","unstructured":"Zhao J, Chen M, Zhuo C, Huang Y, Zheng L, Wang Q. The effect of renin-angiotensin system inhibitors on the recurrence of atrial fibrillation after catheter ablation. Int Heart J. 2020, 61:1174-82. 10.1536\/ihj.20-346","journal-title":"Int Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505992-serum-potassium-and-mineralocorticoid-receptor-antagonists-as-modifiers-of-atrial-arrhythmia-recurrence-after-catheter-ablation-for-atrial-fibrillation-a-narrative-review-with-systematic-search-and-mechanistic-synthesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:29:22Z","timestamp":1787441362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505992-serum-potassium-and-mineralocorticoid-receptor-antagonists-as-modifiers-of-atrial-arrhythmia-recurrence-after-catheter-ablation-for-atrial-fibrillation-a-narrative-review-with-systematic-search-and-mechanistic-synthesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.114995","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}